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Background: Effective gene transfer to the pancreas or to pancreatic cells has remained elusive although it is
essential for studies of genetic lineage tracing and modulation of gene expression. Different transduction methods
and viral vectors were tested in vitro and in vivo, in rat and mouse pancreas.
Results: For in vitro transfection/transduction of rat exocrine cells lipofection reagents, adenoviral vectors, and
Mokola- and VSV-G pseudotyped lentiviral vectors were used. For in vivo transduction of mouse and rat pancreas
adenoviral vectors and VSV-G lentiviral vectors were injected into the parenchymal tissue. Both lipofection of rat
exocrine cell cultures and transduction with Mokola pseudotyped lentiviral vectors were inefficient and resulted in
less than 4% EGFP expressing cells. Adenoviral transduction was highly efficient but its usefulness for gene delivery
to rat exocrine cells in vitro was hampered by a drastic increase in cell death. In vitro transduction of rat exocrine
cells was most optimal with VSV-G pseudotyped lentiviral vectors, with stable transgene expression, no significant
effect on cell survival and about 40% transduced cells. In vivo, pancreatic cells could not be transduced by
intra-parenchymal administration of lentiviral vectors in mouse and rat pancreas. However, a high efficiency could
be obtained by adenoviral vectors, resulting in transient transduction of mainly exocrine acinar cells. Injection in
immune-deficient animals diminished leukocyte infiltration and prolonged transgene expression.
Conclusions: In summary, our study remarkably demonstrates that transduction of pancreatic exocrine cells
requires lentiviral vectors in vitro but adenoviral vectors in vivo.
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The pancreas is a mixed gland with an exocrine and an
endocrine component. The exocrine portion makes up
more than 95% of the volume of the pancreas, the endo-
crine portion 1–2% [1]. The exocrine pancreas consists
of duct, centroacinar and acinar cells, the latter being
the most abundant cell type. Acinar cells produce digest-
ive enzymes which they secrete into the duodenum via
ducts. In 2 major pancreatic pathologies, pancreatitis
and pancreas cancer, the acinar cells are replaced by
duct cells, a process termed acinoductal metaplasia [2].
Pancreas cancer has a dismal prognosis: the overall 5-
year survival rate among patients with pancreas cancer
is less than 6% [3]. Exocrine tumours are the most com-
mon form of pancreas cancer from which 95% are* Correspondence: ihoubrac@vub.ac.be
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distribution, and reproduction in any mediumpancreatic ductal adenocarcinomas (PDAC). PDAC is
thought to arise from ductal precursor lesions, including
pancreatic intraepithelial neoplasias (PanIN), which ac-
cumulate mutations and become progressively dysplas-
tic, finally forming metastatic tumours [4]. Many recent
studies in mice indicate by genetic lineage tracing that at
least a part of PDAC and PanIN arise from acinar cells
that are reprogrammed into a preneoplastic state [4-8].
Lineage tracing also revealed acinar-to-ductal transdif-
ferentiation, both in caerulein-induced pancreatitis and
following pancreatic transforming growth factor alpha
overexpression in mice [9,10]. In addition, cultured aci-
nar cells from mice [11,12] and humans [13] can trans-
differentiate to duct cells.
Also in the context of diabetes mellitus the acinar cells
represent an interesting cell population of the pancreas.
Diabetes is a group of metabolic diseases characterized
by high blood glucose levels which result from defects in
insulin secretion, or action, or both. It is a major andntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Beta cell transplantation can restore the functional beta
cell mass in diabetic patients but it is seriously hampered
by donor shortage. This problem could be solved by
generating more beta cells by reprogramming more
readily available cell types unaffected by the disease. Aci-
nar cells, the most abundant cell type in the pancreas,
represent an attractive source for beta cell replacement
therapy. Lineage tracing studies in vitro as well as
in vivo have clearly shown that rodent acinar cells can
be converted into functional beta cells [14-17]. The
ability of acinar cells to become reprogrammed is further
supported by acinar transdifferentiation into hepatocytes
[18,19] and adipocytes [20]. Their remarkable plasticity
and their involvement in 3 major pancreas pathologies
make acinar cells a highly interesting cell type. Obvi-
ously, an efficient method for gene delivery in pancreatic
acinar cells would be a useful tool for genetic lineage
tracing, overexpression and knock-down studies, and for
gene therapy. Several viral vectors such as adenoviral
vectors [13,15,17,21-28], lentiviral vectors [29-34] and
adeno-associated viral vectors (AAV) [27,35-37] have
been used for gene delivery in pancreas. Although long-
term and robust gene transfer in pancreas has already
been achieved with AAV vectors and despite several
advantages of AAV vectors compared to other vectors
such as very low immunogenicity, replication defective-
ness, lack of pathogenicity and broad tropism, their
major disadvantage of a limited cloning capacity pre-
cluded their usage in this study. Because of this charac-
teristic, AAV vectors are less suitable for delivery of
larger genes for lineage tracing or overexpression stud-
ies. In this comparative study, we opted for lentiviral and
adenoviral vectors, next to lipofection. The different
transfection/transduction methods were tested in vitro
and in vivo in rat and mouse pancreas. We conclude
that vesicular stomatitis virus-glycoprotein (VSV-G)
pseudotyped lentiviral vectors are the most optimal for
in vitro gene transfer, whereas for in vivo transduction
of rodent pancreas, adenoviral transduction reached the
highest efficiency.
Results
In vitro transfection of exocrine pancreatic cells is
inefficient
Primary cultures of exocrine cells isolated from rat pan-
creas were transfected with 2 different commercial lipo-
fection reagents, lipofectamine 2000 (cationic liposome)
and effectene (a two-component non-liposomal lipid for-
mulation). Transfection was performed on the day of
isolation with pEGFP-N2 (day 1) and the efficiency was
determined by analyzing the percentage of enhanced
green fluorescent protein (EGFP)+ cells. While it is
reported that cell lines of the exocrine pancreas couldbe transfected at high yields using lipofectamine
2000 [13,38-41], we found that less than 0.1% of primary
cells were transfected and expressed EGFP (not shown).
When varying amounts of plasmid DNA and varying
ratios of DNA to effectene reagent were used, EGFP+
cells appeared 24 hours after transfection (Additional
file 1: Figure S1) but only ≤ 3.7% of total cells expressed
EGFP on day 8 (Figure 1). A similar efficiency was
obtained at earlier time points (Additional file 1:
Figure S1).
In vitro transduction of rat exocrine pancreatic cells using
mokola and VSV-G pseudotyped lentiviral vectors
The efficiency of Mokola and VSV-G pseudotyped lenti-
viral vectors was compared in transducing isolated rat
exocrine pancreatic cells. Transduction was performed
on day 1 (the day of isolation) with a recombinant lenti-
viral vector that expressed EGFP under the control of
the ubiquitous and constitutively active cytomegalovirus
(CMV) promoter (LeCMV-EGFP) and whose envelope
was pseudotyped with glycoproteins either from Mokola
virus (LeMoCMV-EGFP) or from VSV (LeVSV-GCMV-
EGFP). During culture, EGFP was stably expressed
(Figure 2A-F) and on day 8, the fraction of EGFP+ cells
was counted at different MOI’s (Figure 2G). The effi-
ciency to transduce isolated rat exocrine cells with
LeVSV-GCMV-EGFP was 8 to 11 times higher than with
LeMoCMV-EGFP at multiplicity of infection (MOI) 5
and MOI 10. Transduction with LeVSV-GCMV-EGFP at
MOI of 50 resulted in 41.9 ± 2.6% EGFP+ cells on day 8
(Figure 2 F,G).
Comparison of in vitro adenoviral and lentiviral
transduction of rat exocrine cells
To compare the transduction efficiency of adenoviral
(AdCMV-EGFP) or lentiviral (LeVSV-GCMV-EGFP) vec-
tors, rat exocrine pancreatic cells were transduced for 4
hours on day 1 (the day of isolation). After the 4 hours
transduction period, EGFP was already weakly detectable
in adenovirally transduced cells (Additional file 2: Figure
S2), whereas no EGFP was observed in the lentivirally
transduced cells on day 1 (not shown). The number of
EGFP+ cells and the amount of protein per cell
increased with increasing MOI’s (Additional file 2:
Figure S2). Lentiviral expression of EGFP reached a plat-
eau only at day 3 (Figure 3G). During the first days fol-
lowing transduction, adenoviral transduction of rat
exocrine cells resulted in high efficiencies and a very
high level of transgene expression, even at MOI 1, as
compared to LeVSV-GCMV-EGFP (Figure 3). However,
from day 4 on, massive cell death occurred in the adeno-
virally transduced cells and the formation of monolayers
was disturbed (Figure 3C-E). On day 8, only 31.7 ± 5.3%
(n=3) of the adenovirally transduced cells survived, while
Figure 1 Transfection of isolated rat exocrine pancreas cells with effectene. Quantification of the percentage EGFP expressing cells on day
8 in culture after transfection of rat exocrine pancreas on day 1 with pEGFP-N2 and effectene with varying amounts of plasmid DNA and ratios of
DNA/effectene.
Figure 2 Transduction of isolated rat exocrine pancreas cells using Mokola and VSV-G pseudotyped lentiviral vectors. (A-F) Day 3 in
culture of transduced rat exocrine pancreas cells with LeMoCMV-EGFP (A) MOI 5, (B) MOI 10 or (D) LeVSV-GCMV-EGFP MOI 5, (E) MOI 10, (F) MOI
50. (C) Untransduced cells showed no fluorescence. The expression of the reporter increased with higher MOI and was better in LeVSV-GCMV-EGFP
as compared to LeMoCMV-EGFP. Merged pictures of bright field and green fluorescence. (G) Quantification of the percentage of EGFP expressing
cells on day 8 in culture after transduction with LeMoCMV-EGFP or LeVSV-GCMV-EGFP of rat exocrine pancreas on day 1.
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Figure 3 Culture of AdCMV-EGFP and LeVSV-GCMV-EGFP transduced rat exocrine pancreas cells. (A-J) Culture of rat exocrine pancreas cells
transduced with (A-E) AdCMV-EGFP MOI 1 and (F-J) LeVSV-GCMV-EGFP MOI 50, (A, F) day 2, (B, G) day 3, (C, H) day 4, (D, I) day 5 and (E, J) day 7
in culture. Adenoviral transduction resulted in higher transduction efficiencies and higher levels of EGFP expression on (A) day 2 and (B) day 3,
when compared to the lentiviral vectors (F-G). However, from (C) day 4 on, massive cell death occurred in the adenovirally transduced condition
and the monolayer formation was disturbed. On the contrary, the cell viability in lentivirally transduced cells remained normal and they had a
strong and stable expression of the transgene.
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was comparable to that of non-transduced cells and
showed normal monolayer formation and stable trans-
gene expression (Figure 3F-J).
In vivo transduction of pancreatic cells with
lentiviral vectors
To investigate the efficiency of in vivo transduction with
LeVSV-GCMV-EGFP, viral vectors were injected into
the pancreatic parenchyma of CD1 mice (n = 5). A range
of 0 - 107 transducing units (TU) was used. Injection of
the lectin wheat germ agglutinin coupled to tetramethyl
rhodamine isothiocyanate (WGA-TRITC) was previously
shown to result in specific binding to acinar cells and
served as a control for the injection [14]. Pancreata
were analysed for lectin labelling and EGFP expression
by endogenous fluorescence in cryosections of the
pancreas and by immunohistochemistry with anti-greenfluorescent protein (GFP) on paraffin sections on day 7
following viral vector injection. Under these conditions
pancreas histology remained normal. However, while
lectin-bound TRITC was easily detectable, no EGFP
could be observed in viral vector-injected pancreata
(Additional file 3: Figure S3). Similarly, no EGFP+ cells
could be detected 7 days following injection of different
amounts of LeVSV-GCMV-EGFP in the parenchyme of
rat pancreas (n = 9) (between 0 and 4 × 107 TU) (not
shown). In conclusion, pancreatic cells could not be
transduced in vivo by intra-parenchymal administration
of lentiviral vectors.
In vivo transduction of pancreatic cells by
adenoviral vectors
In contrast with the previous in vitro observations,
in vivo administration of adenoviral vectors into the par-
enchyma of mouse and rat pancreas resulted in high
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(n = 14) was injected with different amounts of
AdCMV-EGFP (0–5 × 109 plaque forming units (Pfu)
at multiple sites. Injection of WGA-TRITC was used
as a control. Samples were analyzed at day 4 (n = 6), 7
(n = 4), 9 (n = 2) and 12 (n = 2) after injection. On day
4 several lobes of the pancreas showed a high expression
level of EGFP (Figure 4A). EGFP was already detectable
at a dose of 108 Pfu AdCMV-EGFP and continuously
increased as higher amounts of adenoviral vectors
were used. However, even at the highest dose used, some
pancreatic regions remained negative. The expression of
transgene peaked on day 4 (Figure 4A) and diminished
with time (Figure 4 A,C,E) to reach zero level at day 12
(not shown). Haematoxylin-eosin stainings showed local
inflammation and infiltration of leukocytes on day 4 with
a gradual restoration of normal pancreas histology
over time (Figure 4B,D,F). Leukocyte infiltration could
no longer be detected at day 12 after transduction
(not shown).
AdCMV-EGFP (109–5 × 109 Pfu in a volume of 200 –
600 μl of physiologic fluid) were injected at multiple
sites in the parenchyma of Wistar rat pancreas. Analysis
was done at days 3 (n = 11), 6 (n = 6), 7 (n = 3), 8
(n = 2), and 10 (n = 2). Immunohistochemical detection
of EGFP revealed that the higher the volume, the moreFigure 4 Intra-parenchymal administration of AdCMV-EGFP in mouse
injected with (A, B) 109 Pfu AdCMV-EGFP analysed on day 4 after injection
day 9 after injection. (A, C, E) Immunohistochemical staining for EGFP in re
Comparison of intra-parenchymal injection of 5 × 109 Pfu AdCMV-EGFP in (
immune-deficient (RNU) rats, analysed (G-J) on day 4 and (K-N) day 7 after
and DNA in blue. (I-J, M-N) Haematoxylin-eosin staining.epithelial cells were transduced (not shown). At a con-
stant number of viral vectors (5 × 109 Pfu) in a small in-
jection volume (200 μl), mesenchymal cells between
pancreatic lobes and peripherally located epithelial
cells were transduced, whereas with a higher volume
(≥ 400 μl) a high transduction efficiency was observed in
the centre of the pancreatic lobes (not shown). Also,
with increasing numbers of adenoviral vectors, increas-
ing numbers of EGFP+ cells were detected, similar to
the results seen in mice (not shown). However, some
regions remained negative for the transgene as well. As
in mice, the reporter expression was maximal on day
3–4 (Figure 4G and not shown) but declined over time
more rapidly than in mice (Figure 4G,K) and was
completely absent by day 10 (not shown). Clear signs of
local inflammation and leukocyte infiltration were
present on day 3–4 and gradually decreased with time
(Figure 4I,M). Analysis of consecutive sections showed a
clear overlap of inflammatory regions and regions
expressing EGFP, as expected (not shown). Double
immunohistochemical staining for EGFP and amylase
revealed that the majority of the transduced cells both in
mice and rats are acinar cells. However, also synaptophy-
sin, insulin or glucagon positive islet cells and some
keratin 19-positive duct cells were transduced, albeit at a
lower efficiency (Figure 5). In summary, injection ofand rat pancreas. (A-F) Paraffin sections of the pancreas of CD1 mice
, (C-F) with 2 x 109 Pfu AdCMV-EGFP analysed (C-D) on day 7 or (E-F)
d and DNA in blue. (B, D, F) Haematoxylin-eosin staining. (G-N)
G, I, K, M) immune-competent (Wistar) rats and (H, J, L, N)
injection. (G-H, K-L) Immunohistochemical staining for EGFP in red
Figure 5 Double immunohistochemical stainings on mouse and rat pancreas injected intra-parenchymal with AdCMV-EGFP. (A-G)
Immunohistochemical staining in red for EGFP and in green (A-B) for amylase, (C, E) keratin 19, (D) insulin, (F) glucagon, (G) synaptophysin.
(A, C, E-F) Mouse pancreas injected with 109 Pfu AdCMV-EGFP. (B, D) RNU rat injected with 5 × 109 Pfu AdCMV-EGFP. (G) Wistar rat injected with
5 × 109 Pfu AdCMV-EGFP. Arrows indicate double positive cells for EGFP and keratin 19. The inset in C is a higher magnification.
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creas resulted in high transduction efficiency but was ac-
companied by inflammation, and transgene expression
was transient.
In vivo transduction of pancreatic cells from
immune-deficient rodents with adenoviral vectors
In order to further improve in vivo transduction of the
pancreas, a preliminary study was conducted to compare
immune-deficient with immune-competent rodents.
Immune-deficient BALB/c Nu/Nu mice (n = 4) were
transduced with 2 × 109 Pfu of AdCMV-EGFP as
described above and were compared to wild-type BALB/
c mice (n = 4). Analysis was done at day 4 and at day 7
after injection. The preliminary results indicate that the
effects of in vivo pancreas transduction in BALB/c micewere similar as in CD1 mice, with a high level of re-
porter expression seen on day 4 and less on day 7, while
areas of the transduced pancreas contained inflamma-
tory cells at both time points. Expression of the trans-
gene in BALB/c Nu/Nu mice on day 4 was comparable
with the immune-competent mice. However, at day 7
the expression remained high in the immune-deficient
mice and less inflammation was present (not shown).
Also in rats a preliminary comparative study was per-
formed of in vivo adenoviral pancreas transduction in
immune-competent (Wistar) (n = 4) and immune-
deficient (RNU/RNU) animals (n = 6). All animals
received 5 x 109 Pfu. Two animals from each group were
analyzed on day 4, 7 and 14 after injection. The
immune-deficient nude rats responded in a similar way
as the immune-deficient BALB/c Nu/Nu mice. On day 4
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sion of the reporter between immune-deficient rats and
immune-competent rats, but pancreata of nude rats con-
tained much less inflammation (Figure 4G-J). On day 7,
EGFP expression was low in Wistar rats, whereas it
remained high in nude rats (Figure 4K-N). In nude rats
the structure of the pancreas looked normal by day 7 in
contrast to Wistar rats (Figure 4M-N). Even after 14
days, expression of the transgene remained high in the
nude rats, in contrast to immune-competent animals
(not shown). In conclusion, pancreatic cells could be ef-
ficiently transduced in vivo by intra-parenchymal admin-
istration of adenoviral vectors in rat and mouse
pancreas. Highest efficiency was seen in acinar cells, and
pancreatic histology was severely affected in normal pan-
creas but preliminary results indicated nearly normal
pancreas histology in immune-deficient animals.
Discussion
In the search for methods for efficient gene delivery into
pancreatic acinar cells, we have investigated different
viral and non-viral vectors in vitro and in vivo. Non-viral
in vitro transfection of primary exocrine pancreatic cells
only reached very low efficiency. Lipofectamine 2000,
widely used for transfection of cell lines, has, to our
knowledge, not been reported before for transfection of
exocrine pancreatic cells. Many studies indicate very
high transfection efficiency in rapidly dividing cells
[13,38-41]; while in non-dividing human pancreatic islets
lipofectamine 2000 resulted in low transfection efficiency
[42]. We have demonstrated previously that the exocrine
cells in our cultures show a very limited proliferative
capacity [12,43], a possible explanation for the observed
low transfection efficiency. Another study indicated that
trypsin-dispersion of human, rodent and foetal porcine
islets increased the efficiency of gene transfer with lipo-
fectamine 2000 [44]. Our unpublished results showed
that enzymatic and non-enzymatic dispersion of exo-
crine cell clusters had a dramatic negative effect on cell
survival. The efficiency of transfections with the non-
liposomal lipid effectene in primary cells is dependent
on the cell type: some primary cell types were reported
to express high amounts of the transgene [45-47] while
others showed a low efficiency of transfection [48] com-
parable to our results.
In general, viral vectors are more efficient than
non-viral vectors for gene transfer. One way to alter the
tropism of a viral vector is pseudotyping, i.e. the incorp-
oration of heterologous envelope proteins in the vector.
The most widely used envelope for lentiviral vectors is
VSV-G, as it provides the vectors with a very broad host
range, and the viral particles can easily be concentrated
by ultracentrifugation. For the in vitro transduction of
rat exocrine pancreatic cells, we also tested Mokolapseudotyped lentiviral vectors. Mokola is a rabies-related
virus and belongs to the family of Rhabdoviridae, as ves-
icular stomatitis virus does. Mokola pseudotyped lenti-
viral vectors have been used for the transduction of a
variety of cell types, especially brain cells such as neu-
rons, oligodendrocytes, and astrocytes [49-51] but also
skeletal and cardiac myocytes [52], satellite cells [53],
skin fibroblasts [54], retinal pigment epithelium [55-57]
and alveolar epithelium [58]. With the exception of the
study of Kobinger et al. [31], in which only a very limited
expression of the transgene was shown in human islet
cells, they have not been used for the transduction of
pancreatic cells. VSV-G pseudotyped lentiviral vectors
have also been used for the delivery of genes into various
cell types in vitro, including human and rodent pancre-
atic islets [29,30,32,33]. However, they have not been
used for the transduction of pancreatic acinar cells
in vitro. We report that VSV-G pseudotyped lentiviral
vectors have an 8–11 times higher efficiency to trans-
duce rat exocrine acinar pancreatic cells compared to
Mokola pseudotyped lentiviral vectors at comparable
MOI. The transgene expression reached a plateau at 48
hours following transduction, remained stable through-
out the culture period and did not affect the viability of
the cells. Adenoviral vectors, on the other hand, have
been reported to induce a very early and titer-dependent
expression of the transgene in pancreatic acinar cells
in vitro with a very high expression level after 24 hours
[15,21-23,25,28], which is comparable to what we
observed. Therefore, for short-term culture, adenoviral
vectors are very efficient in gene transfer. However, later
in culture they induced a considerable amount of cell
death. This has not been reported in the abovemen-
tioned studies, since the acinar cells were mostly kept in
culture only for 24 hours [21-23] and at maximum for 4
days [15].
The results of in vivo intra-parenchymal delivery of
lentiviral vectors in the pancreas are in sharp contrast
with the high efficiency during in vitro lentiviral trans-
duction. A similar report has been published, in which
no significant transduction of the pancreas by intra-
parenchymal injection of lentiviral vectors was reported
[35]. On the contrary, intra-ductal administration of len-
tiviral vectors in the mouse pancreas efficiently trans-
duced acinar cells [34]. In vivo transduction efficiencies
do not always correlate with in vitro efficiencies
[27,35,59]. The remarkable difference in transduction ef-
ficiency of lentiviral vectors in vitro and in vivo might be
explained by lentiviral instability in the presence of
serum [35,60-63]. Lentiviral vectors also have a relatively
large virion size which could affect their capacity to per-
fuse the tissue [35].
Adenoviral vectors have been used previously to
transduce pancreatic cells in vivo via different routes:
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parenchymal [17,27]. Although adenoviral vectors show
a high efficiency of transduction, they also elicit an im-
mune response. Our preliminary results in immune-
deficient nude mice and rats indicated considerably less
tissue inflammation. Similar observations have been
reported with Rag −/− immune-deficient mice [17].
Several mechanisms may account for the transient
transgene expression following adenoviral transduction,
both in vivo and in vitro. The adenoviral episome may
be eliminated in cells that are replicating, since it does
not integrate into the host genome. Furthermore, acute
direct toxicity of adenoviral proteins has been described
[65,66]. Also, some adenoviral gene products induce
apoptosis [67]. Residual expression of adenoviral genes
in islet cells in vitro was sufficient to modulate cell death
[68]. Moreover, it has been reported that the transgene
itself also can induce increased cell death [66,69]. How-
ever, in the current study the latter is very unlikely since
lentiviral overexpression of EGFP did not induce cell
death. The presence of inflammatory infiltrates in the
pancreas after intra-parenchymal delivery of adenoviral
vectors and the increased duration of transgene expres-
sion in immune-deficient animals indicate that the eli-
cited immune response limited the transgene expression.
Conclusions
We demonstrated that VSV-G pseudotyped lentiviral
vectors provide the best transduction efficiency with op-
timal cell viability for in vitro gene delivery to exocrine
pancreatic cells as compared to adenoviral vectors,
Mokola pseudotyped lentiviral vectors and lipofection.
Remarkably, direct intrapancreatic injection of lentiviral
vectors in rodents was highly inefficient. For in vivo
transduction of rodent pancreas, adenoviral vectors were
superior and our preliminary results in immune-
deficient animals were very promising . Mainly exocrine
acinar cells were targeted. Acinar cells represent an
interesting cell type to study in the context of pancreatic
pathology and regenerative biology, since their transdif-
ferentiation potential has already been extensively docu-
mented [4-11,13-17,19,20]. The gene transfer methods
that we have developed in this study will be helpful not
only to allow genetic lineage tracing but also for gain-
and loss-of function studies in order to obtain a better
understanding of acinar cell plasticity.
Methods
Animals
The following animals were used for the in vivo adminis-
tration of viral vectors: male CD1 mice weighing 38–51
g (Crl:CD1(ICR)) (Charles River Laboratories, L’Arbresle
Cedex, France), male BALB/c mice weighing 23–25 g
(BALB/cAnNCrl) (Charles River Laboratories), maleBALB/c Nude Mice weighing 21–24 g (CAnN.Cg-
Foxn1nu/Crl) (Charles River Laboratories), male Wistar
Han rats weighing 210–350 g (Crl:WI(Han) (Charles
River Laboratories), male Rowett nude rats weighing
180–210 g (HsdHan™:RNU-Foxn1rnu (Harlan, Horst,
the Netherlands)). Male 10–12 week old Wistar rats
(Janvier, Le Genest-St-Isle, France) weighing 250–300 g
were used for the isolation of cells from the pancreas.
Pancreata were partially dissociated with collagenase and
exocrine acini were purified by centrifugal elutriation as
published before [12]. All animal experimentation
was approved by the Ethical Committee of the Free
University of Brussels.Culture procedure
After isolation, the cell density of the suspension of rat
exocrine cells was determined using a haemocytometer.
Therefore, a representative sample of the cell suspension
was centrifuged, followed by trypsinisation (Sigma) for 5
minutes at 37°C. The cells were washed with standard
medium with 10% serum (see below) and were then
lysed and stained by propidium iodide lyse buffer (so-
dium citrate (1 g/l), propidium iodide (50 mg/l), tritonX
(0.1%)). The nuclei were counted in a Bürker chamber.
The exocrine cells were pre-cultured for 4 days in
bacteriological Petri dishes (Nunc, Langenselbold,
Germany) in Advanced RPMI-1640 medium (Invitrogen,
Merelbeke, Belgium) supplemented with 10% foetal
bovine serum (FBS) (Gibco, Invitrogen), glutamax-I
(Gibco, Invitrogen) and penicillin-streptomycin solution
(100 U/l - 100 mg/l) (Sigma, St Louis, MO, USA) at 37°C
in a humidified atmosphere of 5% CO2. Geneticin
sulphate (50 μg/ml) (Sigma) was used to suppress fibro-
blast overgrowth in the culture. Medium was replaced
daily during this preculture period. At the end of the pre-
culture, cells were transferred to 24-well plates (Falcon,
BD Biosciences, Erembodegem, Belgium) to form adher-
ent cultures. Adherent monolayers were further cultured
with RPMI supplemented with 1% FBS and antibiotics
and 50 ng/ml human recombinant epidermal growth fac-
tor (Sigma) [43].Transfection
Rat exocrine cells were transfected with pEGFP-N2 on
the day of isolation (day 1) using lipofectamine 2000
(Invitrogen) or effectene (Qiagen, Venlo, Netherlands)
according to the manufacturer’s protocol in suspension
24-well plates (Greiner Bio-one, Frickenhausen, Ger-
many) or 35 mm suspension dishes (Nunc). After 4
hours transfection with lipofectamine 2000, the medium
was changed to the standard medium with antibiotics
and the cells were cultured according to the standard
protocol.
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After isolation, the rat exocrine cells were transduced by
adenoviral or lentiviral vectors (day 1) in minimal
amounts of medium without serum for 4 hours in sus-
pension 24-well plates (Greiner Bio-one) or 35 mm sus-
pension dishes (Nunc). Different multiplicities of
infection were used. Then the cells were washed three
times and cultured according to the standard protocol.
Viral vector production
Recombinant replication-deficient adenoviral vectors
expressing EGFP (AdCMV-EGFP) were generated fol-
lowing standard techniques as described by He et al
[70]. Therefore the AdEasyTM adenoviral vector system
(Agilent technologies, Diegem, Belgium) was used. The
adenoviral plasmids were produced by homologous
recombination in electro competent E.coli BJ5183
cells between the adenoviral backbone plasmid vector,
pAdEasy-1, and a shuttle vector pAdTrack. pAdEasy-1
contains most sequences from human adenovirus
serotype 5 with deletion of the genes E1 and E3; the
pAdTrack vector is a shuttle vector for production of
EGFP-trackable viral vectors. The adenoviral vectors
were then produced by transfection in 293E1 cells [70].
The lentiviral vectors used are third generation lenti-
viral vectors with as main features: the vectors are self
inactivating (SIN) (promoter activity in the U3 region
of the long terminal repeat (LTR) has been deleted
(DeltaU3)) and they contain the DNA flap region also
named Triplex or central purine pyrimidine track (cPPT)
that is crucial for optimal transport of the reverse tran-
scribed dsDNA into the nucleus [71]. Recombinant len-
tiviral vectors (LeCMV-EGFP) were produced by
transient transfection of 293T cells according to standard
protocols [72] with some modifications. Briefly, 293T
cells were cotransfected with the packaging plasmid
pCMVdeltaR8.74, the envelope plasmid pMD2.G encod-
ing for VSV-G or Mokola envelope, and the transfer vec-
tor pTrip-CMV-EGFP-deltaU3 [73]. After 6–8 h the
medium was changed and lentiviral vectors were har-
vested 48 h and 72 h later. Supernatants were treated
with DNase (Roche, Vilvoorde, Belgium), filtered
through a 0.22-μm-pore-size filter, and concentrated by
ultracentrifugation in a Beckman SW28 rotor (Optima
LE-80K ultracentrifuge; Beckman Coulter, Palo Alto,
CA) for 90 min at 22 000 rpm. After ultracentrifugation,
the pellet was resuspended in phosphate buffered saline,
divided into aliquots and frozen at −80°C until use. Len-
tiviral vectors were titrated as described [74].
Microscopy and immunohistochemistry
Microscopic images were acquired with a Nikon TE2000-
E microscope using NIS AR2.30 Imaging Software (Nikon
France SAS, Champigny-sur-Marne, France) and with aLeica DM IRBE microscope using Axiovision 3.1 software
(Carl Zeiss, Zaventem, Belgium). Pictures were taken from
living cell cultures as well as from fixed, stained material.
For in vitro culture, the cells were fixed on day 8 with
formaldehyde (Labonord, Templemars, France) for 10 min
at room temperature. The monolayer was covered
with Vectashield containing 40,6-diamidino-2-phenylindole
(Vector Laboratories, Burlingame CA94010, USA). To
determine the efficiency of transfection/transduction,
the native fluorescence of EGFP of at least 1000 cells
per condition was evaluated.
For immunohistochemistry, the pancreata were fixed
with formaldehyde (Labonord, Templemars, France) for
4 h, dehydrated and embedded in paraffin. Paraffin sec-
tions of 4 μm were cut. Alternatively, the pancreata were
fixed for 4 hours in cold 4% paraformaldehyde (Sigma),
soaked overnight in 20% sucrose solution, embedded in
optimal cutting temperature compound (Labonord) and
frozen in liquid nitrogen. Frozen sections of 5 μm were
cut. The indirect method with fluorochrome-labelled
secondary antibodies was used. Secondary antibodies
directly coupled to tetramethyl rhodamine isothiocyan-
ate, fluoresceinisothiocyanate or cyanine 2 were pur-
chased from Jackson ImmunoResearch Laboratories
(West Grove, PA., USA). The primary antibodies were:
1/500 rabbit anti-amylase (Sigma), 1/100 goat anti-GFP
(Abcam, Cambridge, UK), 1/3000 rabbit anti-glucagon
(Prof. C. Van Schravendijk, Brussels), 1/2000 mouse
anti-glucagon (Sigma), 1/3000 guinea pig anti-insulin
(Prof. C. Van Schravendijk, Brussels), 1/100 rat anti-
cytokeratin 19 (Hybridoma bank), 1/1000 rabbit
polyclonal anti-keratin (Dako, Glostrup, Denmark) and
1/10 rabbit anti-synaptophysin (Novocastra, Zaventem,
Belgium).In vivo transduction
Mice were anesthetized by i.p. injection with a mixture of
ketamine (75 mg/kg) and medetomidine (1 mg/kg), rats
by i.p injection of Nembutal. Exposure of pancreas was
performed via laparotomy through midline incision. The
lentiviral and adenoviral vector solutions were microin-
jected directly into the pancreatic parenchyma at multiple
sites. In mouse pancreas, we injected in both head and tail
part of the pancreas; in rat pancreas, only injections in the
tail part were performed. Injections with wheat germ ag-
glutinin, coupled to tetramethyl rhodamine isothiocyanate
(Invitrogen) were used as a control [14].Additional files
Additional file 1: Figure S1. Shows images of rat exocrine pancreas
cells after in vitro transfection with effectene on day 2 and day 7 in
culture.
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Additional file 3: Figure S3. Shows immunohistochemistry of mouse
pancreas after intra-parenchymal administration of
LeVSV-GCMV-EGFP with or without lectin.
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